Rosiglitazone and LG268 activate a consensus PPRE-luciferase reporter but not the matrix metalloproteinase (MMP) direct repeat-1/activator protein-1 (DR-1/AP-1) reporters. SW-1353 cells were seeded in six-well plates and transfected with 2 μg/well of the (a) PPRE-Luc, (b) MMP1-ENDOG-Luc, or MMP13-ENDOG-Luc (see Materials and methods) luciferase reporter constructs and then treated for 24 hours with 50 nM LG268, 50 nM rosiglitazone, or both drugs together, followed by no treatment or 1 ng/mL interleukin-1-beta (IL-1β) for 24 hours. Cells were solubilized in passive lysis buffer, and equal amounts of protein were loaded for each sample and assayed for luciferase activity as reported in relative light units (RLU). Error bars represent standard deviations of biological triplicates. P values were calculated using the Student t test (*P < 0.05, **P < 0.005, ***P < 0.0005). In (a), there was no statistical difference (P > 0.2) between the nuclear receptor ligand-treated samples and their corresponding IL-1β-treated counterparts (for example, rosiglitazone versus rosiglitazone + IL-1β). In (b), P values represent the IL-1β-treated group versus the non-IL-1β-treated group. 268, LG100268; NoTx, no treatment; PPRE, peroxisome proliferator-activated receptor-gamma response element; Rosi, rosiglitazone.